Hakulinen J, Meri S
Department of Bacteriology and Immunology, University of Helsinki, Finland.
Lab Invest. 1994 Dec;71(6):820-7.
Normal human cells resist the lytic activity of homologous complement (C) by expressing inhibitory molecules on their cell membranes. Recently, it has become increasingly evident that information on C inhibitors on malignant tumor cells is crucial before considering any immunotherapeutic attempts with C-activating antibodies. As one of the most potent inhibitors of C lysis is protectin (CD59), we have examined its expression and function on human breast cancer cells.
Immunofluorescence microscopy was used to detect protectin expression on solid breast tumor samples (N = 12). Using immunoaffinity chromatography, protectin was isolated from the membranes of cultured MCF7 and T47D breast cancer cells. The purified proteins were incorporated into heterologous cells to study their C inhibitory activities. The reactivity of tumor cell protectins with terminal C complexes was examined by sucrose density ultracentrifugation analysis. A chromium release assay was used to study the effects of protectin neutralization on the sensitivity of MCF7 and T47D cells to C-mediated cytotoxicity.
Protectin was found to be strongly expressed by all human breast cancer tumors examined. The affinity-purified protectins had a glycophosphoinositollipid anchor and migrated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis as glycosylated smears of 19 to 25 kilodaltons. Protectin isolated from T47D cells bound to nascent C5b-9 complexes generated in human sera and inhibited C lysis of guinea pig erythrocytes when incorporated into their cell membranes. C-mediated killing of breast cancer cells could be significantly enhanced after treatment of the cells with F(ab')2 fragments of the anti-protectin monoclonal antibody YTH53.1.
Human breast cancer cells resist C membrane attack by expressing protectin on their cell membranes. Neutralization of protectin on the surface of the tumor cells increases their sensitivity to C lysis.
正常人类细胞通过在细胞膜上表达抑制性分子来抵抗同源补体(C)的溶解活性。最近,越来越明显的是,在考虑使用激活补体的抗体进行任何免疫治疗尝试之前,了解恶性肿瘤细胞上补体抑制剂的信息至关重要。作为补体溶解的最有效抑制剂之一,促衰变因子(CD59),我们研究了其在人乳腺癌细胞上的表达和功能。
免疫荧光显微镜用于检测实体乳腺肿瘤样本(N = 12)上促衰变因子的表达。使用免疫亲和层析从培养的MCF7和T47D乳腺癌细胞膜中分离促衰变因子。将纯化的蛋白掺入异源细胞中以研究其补体抑制活性。通过蔗糖密度超速离心分析检测肿瘤细胞促衰变因子与末端补体复合物的反应性。使用铬释放试验研究促衰变因子中和对MCF7和T47D细胞对补体介导的细胞毒性敏感性的影响。
在所检测的所有人乳腺癌肿瘤中均发现促衰变因子强烈表达。亲和纯化的促衰变因子具有糖基磷脂酰肌醇锚,在十二烷基硫酸钠-聚丙烯酰胺凝胶电泳中迁移为19至25千道尔顿的糖基化涂片。从T47D细胞中分离的促衰变因子与在人血清中产生的新生C5b-9复合物结合,并在掺入豚鼠红细胞膜时抑制补体对其的溶解。用抗促衰变因子单克隆抗体YTH53.1的F(ab')2片段处理细胞后,补体介导的乳腺癌细胞杀伤作用可显著增强。
人乳腺癌细胞通过在细胞膜上表达促衰变因子来抵抗补体膜攻击。肿瘤细胞表面促衰变因子的中和增加了它们对补体溶解的敏感性。